No Data
Veritas In Silico's RNA Function Control Patent Gains European Recognition
The Tokyo Stock Exchange Growth Market Index saw a slight increase, performing relatively stronger than the main market on the day.
Tokyo Stock Exchange Growth Market Index 824.57 +1.11 / Volume 0.1 billion 88.98 million shares / Trading value 126.7 billion yen Tokyo Stock Exchange Growth Market 250 Index 644.18 -0.64 / Volume 95.07 million shares / Trading value 93.9 billion yen In today's growth market, the Tokyo Stock Exchange Growth Market Index continued to rise slightly, while the Tokyo Stock Exchange Growth Market 250 Index fell slightly. The number of rising stocks was 399, the number of declining stocks was 172, and the number of unchanged stocks was 34. On the 27th in the USA market, the Dow Inc average was down 333.59 dollars to 4299.
Three key points to watch in the latter session - soft trend due to the rebound from the end of last week.
In the afternoon trading on the 30th, three points should be noted: ･ The Nikkei index fell, showing a weak trend due to the reaction from the end of last week ･ The dollar-yen exchange rate is holding steady, with US interest rates remaining firm ･ The top contributor to the decline is Advantest <6857>, with First Retailing <9983> in second place. ■ The Nikkei index fell, showing a weak trend due to the reaction from the end of last week. The Nikkei index decreased by 301.48 yen, closing at 39,979.68 yen (estimated Volume 0.7 billion, 58.3 million shares) at the end of the morning trading. Last week's US market's Dow Inc experienced a decline of 333.
Veritas In Silico Secures European Patent for RNA Discovery
Veritas In Silico - Signed a joint development and commercialization agreement with Liverpool ChiroChem in the UK.
On the 23rd, Veritas In Silico ＜130A＞ announced that it has signed a joint development and commercialization agreement for RNA-targeted small molecule Pharmaceuticals with Liverpool ChiroChem (LCC). Starting from July 2024, the company will utilize LCC's Shareholding chemical platform PACETM to work with over 1,000 new chiral fragments through its drug discovery platform ibVIS for cancer diseases, rare diseases, and central nervous system diseases.
Veritas In Silico, Liverpool ChiroChem Partner on MRNA-targeted Drug Development
No Data